Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ibn Alhaytham HospitalAMM:IBNH 33 Debt-to-EBITDA is 9.07 as of Mar. 2026, which is 577% above its 10-year median of 1.34. GuruFocus rates AMM:IBNH with a GF Score™ of 33/100 and a GF Value™ of JOD0.84 (Fairly Valued). The stock has 9 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Ibn Alhaytham Hospital ranks worse than 73.01% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ibn Alhaytham Hospital's Debt-to-EBITDA or its related term are showing as below:
AMM:IBNH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -36.44 Med: 1.34 Max: 4.69
Current: 4.69
During the past 13 years, the highest Debt-to-EBITDA Ratio of Ibn Alhaytham Hospital was 4.69. The lowest was -36.44. And the median was 1.34.
AMM:IBNH's Debt-to-EBITDA is ranked worse than 73.01% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs AMM:IBNH: 4.69
Ibn Alhaytham Hospital (AMM:IBNH) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ibn Alhaytham Hospital Debt-to-EBITDA Related Terms
Ibn Alhaytham Hospital Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ibn Alhaytham Hospital's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMM:IBNH vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Ibn Alhaytham Hospital's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibn Alhaytham Hospital Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ibn Alhaytham Hospital's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ibn Alhaytham Hospital's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Ibn Alhaytham Hospital (AMM:IBNH) has a Debt-to-EBITDA of 9.07 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ibn Alhaytham Hospital. This is 577% above median its historical median of 1.34. According to the industry distribution chart, Ibn Alhaytham Hospital ranks #349 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 73%.
Is Ibn Alhaytham Hospital's Debt-to-EBITDA too high?
Ibn Alhaytham Hospital's current Debt-to-EBITDA of 9.07 is 577% above median its 10-year median of 1.34. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. Ibn Alhaytham Hospital's value of 9.07 is 303.1% above this industry median. Based on the distribution chart, Ibn Alhaytham Hospital ranks #349 out of 478 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Ibn Alhaytham Hospital has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ibn Alhaytham Hospital's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ibn Alhaytham Hospital ranks #349 out of 478 companies for Debt-to-EBITDA. This places Ibn Alhaytham Hospital in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. Ibn Alhaytham Hospital's value of 9.07 is 303.1% above this benchmark. While the company's 10-year median is 1.34 vs. the industry median of 2.25, Ibn Alhaytham Hospital has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibn Alhaytham Hospital's current Debt-to-EBITDA of 9.07 is 303.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ibn Alhaytham Hospital. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibn Alhaytham Hospital's current Debt-to-EBITDA is 9.07, which is 577% above median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibn Alhaytham Hospital stock overvalued right now?
Based on GuruFocus' analysis, Ibn Alhaytham Hospital (AMM:IBNH) is currently considered Fairly Valued. The stock's GF Value™ is JOD0.84, compared to a current price of JOD0.86 — trading 2.4% above its estimated fair value. The current Debt-to-EBITDA is 9.07, which is 577% above median its 10-year median of 1.34 and 303.1% above the Healthcare Providers & Services industry median of 2.25. Ibn Alhaytham Hospital's overall GF Score™ is 33/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ibn Alhaytham Hospital (AMM:IBNH), the current Debt-to-EBITDA is 9.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibn Alhaytham Hospital (AMM:IBNH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibn Alhaytham Hospital stock appears to be overvalued.
The current stock price of JOD0.86 is trading 2.4% above its estimated GF Value™ of JOD0.84.
GuruFocus considers Ibn Alhaytham Hospital to be Fairly Valued.
Key valuation signals for AMM:IBNH:
Debt-to-EBITDA: 9.07 (577% above median its 10-year median of 1.34)
GF Value™: JOD0.84 vs. price of JOD0.86 (2.4% above fair value)
Industry Position: 303.1% above the Healthcare Providers & Services median (#349 of 478)
No single metric tells the full story. See the AMM:IBNH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibn Alhaytham Hospital operates as a hospital in Jordan. The Company's main objectives is to found and establish a hospital for general casses And especially ophthalmology, Otorhinolaryngology, Medicine and Neurosurgery and to Import a necessary medical equipment and supplies. The company operates in segments, which comprise of Medical & investments and others.
33GF Score
Get the complete analysis for AMM:IBNH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:IBNH has been successfully added to your 
